Next week, NPC's Jon Campbell, Kimberly Westrich, Tyler Wagner, and James Motyka will be attending and presenting at #AMCP2024 in New Orleans, LA! Will you be there? If so, let us know! If not, you can still register now at the link below. We'd love to connect!

New NPC research was just published in #JMCP ! The study found that low-income and non-white individuals participating in commercial health plans have lower usage of specialty drugs for #autoimmune conditions. Read the full study below.

ICYMI: In Pink Sheet, Citeline Regulatory, John Michael O'Brien recently highlighted the many questions about the current iteration of the #IRA . One such question is what evidence the CMSGov is considering when determining a price for a drug. Read more at the link below!

Research Highlight: #NPC research in the AJMC shows that the Inflation Reduction Act’s Medicare Drug Price Negotiation Program may lead to fewer subsequent indications and delay launches for small molecule drugs. Learn more below! #SOTU2024

Research Highlight: Current Medicare beneficiary access to many of the drugs selected for the 1st round of the #IRA 's Medicare DPNP was high in 2019 & 2023, supporting concerns that the unintended consequences of the IRA may include harm to patient access. #SOTU2024

Our latest study in the AJMC, which was featured today in BioSpace, shows that the #IRA DPNP may unintentionally discourage post-approval small molecule drug research. Read more below ahead of tomorrow's #SOTU2024 : bit.ly/biospace-ira

Last week, Health Affairs launched the #IRA Observatory and #EyeOnTheIRA initiatives to help readers keep up with news and research regarding the implementation of this sweeping piece of legislation. Read more about the project below.

Re-sharing this The New York Times op-ed in honor of #WorldObesityDay today. Check it out below!

At the 5th Annual The Innovation and Value Initiative (IVI) Methods Summit on March 14, Jon Campbell will discuss different approaches to patient-centered #HTA . The panel session will explore real option value and what it means for patients. Join us in DC and help transform the future of healthcare!

We are in a golden age of innovation, with more life-saving medications and treatments being discovered each day. However, to ensure equitable access (particularly for rare disease patients), more innovation is needed in prescription drug policy and how we pay. #RareDiseaseDay

An op-ed in The Wall Street Journal cited our recent publication in Health Affairs Forefront on the unintended consequences of the #InflationReductionAct ahead of #RareDiseaseDay .

Read the The Wall Street Journalopinion article below for more ↓

Saturday at #AccessMiami24 , John Michael O'Brien participated in a session on the “ #IRA and Its Impact in the US and Beyond.” The panel w/ Nancy McGee Lumanity, Lisa Nelson Novartis, Sean Sullivan UW School of Pharmacy, and Jason Spangler The Innovation and Value Initiative (IVI) was part of an important conversation series.

Last week, NPC's Chief Strategy Officer Kimberly Westrich was featured in The Evidence Base as part of the outlet’s coverage of the debate in Washington over quality-adjusted life years ( #QALYs ) and alternatives.

Read the article below!

We expect using price as a factor to have a chilling effect on private and public partnership across the industry, reducing drug research and development and the industry’s willingness to partner with the NIH. Read our full comment letter to the National Institute of Standards and Technology below. #marchinrights

How can @CMSgov promote #healthequity , engage patients & address methodological issues in the #Medicare Drug Price Negotiation Program? Read the actionable recommendations from the symposium hosted by NPC, The Innovation and Value Initiative (IVI), Alliance for Aging Research & Leavitt Partners.

NPC recently submitted comments to the National Institute of Standards and Technology, expressing concerns that using price as a factor when determining whether to exercise march-in rights runs counter to the #BayhDole Act policy objectives of incentivizing and promoting innovation.

Read the comment letter below.

Today: JAMA Health Forum published an NPC research letter on “Medicare Part D Coverage of Drugs Selected for the Drug Price Negotiation Program.” The findings support concerns that the unintended consequences of the #IRA may include harm to patient access.

Learn more ↓

If you're following today's Senate HELP hearing on drug pricing, take a moment to read this from NPC's John Michael O'Brien:

It’s time to stop talking past each other on drug pricing

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program may lead to fewer subsequent indications and delay launches for small molecule drugs, according to our new study published Friday in the AJMC. Learn more at the link below.

Starting soon: Learn about the evolving landscape of #PBMs . Join Fierce's free virtual #JPM2024 panel of experts, including NPC's John Michael O'Brien. Watch today at 10:40 am or watch on demand later. app.ingo.me/q/h1k1f